Tytuł pozycji:
Ocena potencjału terapeutycznego koniugatów glicydylowanych dendrymerów PAMAM generacji czwartej z lapatynibem, fulwestrantem i/lub paklitakselem w chorobach nowotworowych i pasożytniczych
Glycidylated PAMAM G4 dendrimers, due to their low toxicity, can be drug carriers in anticancer therapy. Fulvestrant, lapatinib, and paclitaxel were
attached to glycidylated fourth-generation PAMAM dendrimer, and their antitumor activity was tested on glioma U-118 MG and non-small cell lung cancer A549 cells compared to human non-tumor immortalized keratinocytes. All cell lines used in the study possessed estrogen receptor (ER) and epidermal growth factor receptor (EGFR), therefore they were an excellent therapeutic goal for obtained constructs. Additionally, the synthesized conjugates were tested for antinematode therapy.